A Message from the President

Dear Colleagues and Friends,

We can all be proud of the tremendous growth that our society has achieved over the past year. In keeping with this growth and increased initiatives, we welcome our new Executive Director Chas Haynes and administrative assistant Linda Greer, who with our long-standing matriarch Jan Esenwein provides a solid administrative core and continuity for our society. The work of this cohesive and dynamic team was quite evident at the success of the Orlando meeting, which saw a record number of attendees, a superb Education Day (special thanks to Frederick Lang) and Scientific Program (special thanks to Alfred Yung), as well as being the most financially successful meeting to date. The administrative team is already hard at work on future meetings, with several new excellent initiatives, such as on-line abstract submission. Another example of the activities of our solid administrative core has been the smooth transition of the Editorial Office of our society journal *Neuro-Oncology* to M. D. Anderson. This transition was tremendously assisted from our past Editor-in-Chief Darell Bigner and his editorial staff as well as our journal publisher, Duke University Press. In consultation with our sister organizations EANO and JSNO, a new administrative structure for the editorial board has been organized, with the Editor-in-Chief (from SNO) and Co-Editors from each of the three sister organizations. We thank Darell for his superb stewardship in taking the journal to the highest-impact factor in neuro-oncology, and we look for continued success with Alfred Yung (Editor-in-Chief), David James (Co-Editor: SNO) and other Co-Editors from EANO and JSNO. The journal is one of our highest priorities and deserves continued support from the Society.

SNO has embarked on several new initiatives over the past year to broaden our mandate in taking a leadership role in neuro-oncology. Several new committees have been organized to increase representation and participation of our members. For example, we welcome the nursing community to become full members of SNO. Noreen Leahy has been instrumental in organizing the SNO Nursing Committee and is also the first nursing representative on the SNO Board of Directors. We look forward for this committee to be very active in the future years. Another initiative, and one that is of personal importance to me, is the SNO International Committee. This committee, chaired by Jonathan Finlay and Waldemar Debinsky, is composed of a large number of SNO members representing and willing to facilitate neuro-oncology related activities in many regions of the globe which are currently not served by SNO or its sister organizations. This includes dissemination of DVD sets of the annual meeting, made possible by a generous educational grant from Schering-Plough, and also subsidised free subscriptions to our journal made possible by the generosity of Duke Press. We look forward to the activities of the International Committee, which I believe will have a long term impact for SNO’s mission to play a leadership role in disseminating knowledge in neuro-oncology globally. Several other important initiatives have been set in place and I would urge all members to play an active role in whatever Society activities are of interest.

We continue to receive tremendous support from our longstanding non-profit and corporate sponsors and welcomed several new partners this year. I believe our activities and growth have demonstrated to our partners that indeed we are on track of our mission in “Fostering Advances through Research and Education” in neuro-oncology. We look forward to working with our partners and the SNO Foundation Board as we collectively march ahead with energy to forward our Society, but most importantly help our patients. We look forward to hearing from you and seeing you personally in Dallas.

Abhijit Guha, MD
SNO President
A Message from the Executive Director

Dear Society Members,

It is with great pleasure that I submit this first Annual Report to the Society. I believe that this document marks a major milestone in SNO’s development and is a tangible demonstration of how far the Society has come since its inception.

I think it would be most appropriate at this point to spend a moment of reflection and express our sincere thanks to those who have made this report possible. First and foremost, the Society recognizes the vision of SNO founder Victor Levin, who over a decade ago saw the need to bring together clinicians, basic scientists, and other neuro-oncology specialists to share information and educate one another in a multidisciplinary way. Certainly, SNO’s past presidents, including Edward Shaw, as well as the SNO Foundation Board, should also be acknowledged for their work to ensure a strong financial future for SNO. Abhijit Guha, during his tenure as President, has guided the Society into new and exciting areas. And finally, the Society thanks Jan Eisenwein. SNO’s “spiritual mother”, whose dedication to the Society has been evident since its inception. Today we are an organization with a strong and committed leadership as well as a membership of over 900 representing virtually all disciplines within the neuro-oncology community, as shown in the graph on the last page of this report.

Recently SNO embarked on several new initiatives that we hope will expand our reach and broaden our services to all professionals working in the field of neuro-oncology. Under the guidance of committee chair Jonathan Finlay and co-chairs Waldemar Debinski, we have launched the SNO International Outreach Committee, which is tasked with facilitating neuro-oncology activities on an international level with an emphasis on third world countries. The Committee will be disseminating educational materials including taped lectures, and subsidizing the availability of our journal in under-served areas. Our new Nursing Committee is another effort to broaden our membership by fostering a more visible role for nurses in support of SNO’s multidisciplinary orientation. The Society thanks Noreen Leahy for leading this initiative. You can read more about these new endeavours in the journal section of this report.

During the past year, our official journal, Neuro-Oncology, received an improved impact factor of 4.939—up from 4.150 in 2005—which continues to reflect the journal’s position as the leader in its field. The new rating places Neuro-Oncology 14th among 146 ranked clinical neurology journals and 23rd among 127 ranked oncology journals. SNO is deeply grateful to Darell Bigner, the founding editor of the journal, who in 2006 handed the editorial reins to Alfred Yung. The Society also thanks the Pediatric Brain Tumor Foundation for their invaluable help in launching the journal and for their continued support. Additional information on the journal and its new editorial structure is contained in the journal section of this report.

I am also pleased to report that our 11th Annual Scientific meeting, held in Orlando in November of 2006, was the most successful event in our organization’s history. Abstract submissions were up over 50% and we saw positive gains in both attendance and sponsorship. I am happy to say that after the meeting we were able to add over $200,000 to our long-term investment accounts.

The year ahead holds many opportunities for our Society. We will continue to develop the new initiatives outlined in this report, and will reach out to sister organizations, exploring ways that the SNO administrative office can help in the planning and execution of joint meetings and collaborative projects.

In closing, I would say that it has been an overwhelmingly positive year for our Society. We have generated a great deal of momentum as we move forward. I welcome your comments and ideas for additional areas that SNO can better serve the neuro-oncology community.

J. Charles (Chas) Haynes, JD
SNO Executive Director

A Message from the Foundation

Dear Society Members and Supporters,

The Society is pleased to provide you with the first Annual Report of the Society. This report represents the culmination of five year’s work by the SNO Board of Directors and Foundation Board. The strategic planning process began with the articulation of the Society’s mission: to foster multidisciplinary neuro-oncology research, education and improve patient care. To achieve this goal – to take the Society to the “next level” – it became apparent that a roadmap was needed to ensure financial stability. Four programs were developed, including the Annual Meeting Sponsorship, Partner’s Advisory Council, President’s Club, and the Victor Levin Founder’s Society. The Annual Meeting support program has facilitated growth in the Society’s premier education event. Those non-profit associations, foundations and societies, and corporate donors who support the annual meeting at the highest level with a multi-year commitment are members of the Partner’s Advisory Council, which has direct access to the SNO Board of Directors and Foundation Board on a regular basis. The President’s Club provides annual giving opportunities for individual members of the Society. Through endowment, the future educational and research endeavors of the Society will be supported by the Victor Levin Founder’s Society. As you read through the pages of this Report, consider how you may contribute to the Society with your time or financial resources. Together we are making progress to help our patients live longer and better.

Sincerely,

Victor A. Levin, MD, Mitchel S. Berger, MD and Edward G. Shaw, MD
Since its inception, the Society has served as a platform for disseminating state-of-the-art neuro-oncology research. This is clearly evident in the growing attendance and the quality of the abstracts submitted to the SNO Annual Scientific Meeting. Indeed, the number of submissions has increased so significantly that we added several concurrent sessions to accommodate all the presentations for the 2006 Orlando meeting. We were delighted with the quality of the science presented and truly believe we are bridging the gap between research and practice. Looking ahead, Scientific Committee Vice Chair Russ Pieper is already working on what looks to be an outstanding program for our 2007 meeting in Dallas.

WK Alfred Yung, MD
SNO Scientific Committee Chair

The 2006 meeting started off with an exciting Education Day, chaired by Frederick Lang, which devoted the morning to the Stem Cell Hypothesis of Human Gliomas. Speakers discussed the appropriate definition of cancer stem cells, their potential origin and relation to developmental lineage compartments and role in future research. Counterpoints were also offered, reminding everyone that it is still early days in this new area. After lunch, sessions on clinical research, career development and grant writing as well as immunotherapy and the management of symptoms related to radiation treatment rounded out the educational component.

The Scientific meeting began on Friday with a plenary session on adult therapies that covered novel approaches such as viral therapy and new trials using established drugs including the nitrosoureas. Several excellent cell biology talks elucidated signaling relevant to cancer stem cells, drug resistance and tumorigenicity, and led up to the keynote by Dr. Ronald DePinho who gave an outstanding lecture on his group’s work on the molecular mechanisms of glioma malignancy. After lunch sessions devoted to two of the most active and important areas, the mechanism of resistance to alkylators and the role of 1p/19q deletions in anaplastic oligodendroglioma rounded out the plenary portion of the meeting. Concurrent afternoon sessions on epidemiology, quality of life and symptom management, pathology and genomics as well as cell biology led into the poster sessions. On Saturday pediatrics led off with clinical and translational presentations, followed by a session on molecular genetics, which showcased new developments in using molecular characteristics to distinguish sub-types of glioma. This was followed by a keynote by Dr. Juri Gelovani who described advances in imaging that hold great promise for better definition of the tumor target and more useful approaches for patient follow up. Two more hot areas were discussed after lunch: mouse models and signal transduction inhibitors. These were also reflected in the remaining plenary topics, including angiogenesis and experimental therapeutics. Concurrent afternoon talks discussed radiology, radiation oncology and adult therapies.

On Sunday morning two plenary sessions, on radiology, radiation oncology and adult therapies and on important signaling pathways completed the meeting.

In the future, abstracts for the meeting will be submitted electronically online. The greatly simplified submission process will help both submitters and reviewers, and promises to improve the quality of work presented as well as accessibility to the abstracts.
Spotlight on the Journal

2006 was a milestone for SNO’s official journal, Neuro-Oncology. First and foremost, founding editor Darell D. Bigner stepped down from his position as editor-in-chief and named two highly capable and well-regarded colleagues to replace him: W. K. Alfred Yung of The University of Texas M. D. Anderson Cancer Center in Houston and C. David James of the University of California–San Francisco. Dr. Bigner made inestimable contributions to the success of Neuro-Oncology, and when he stepped down the journal boasted an impact factor of 4.150, putting it on par with such publications as Cellular Oncology, Experimental Cell Research, the British Journal of Cancer, and Cancer Immunology, Immunotherapy. That influence carried over to 2007; today, Neuro-Oncology has an impact factor of 4.939, positioning it 14th among 146 ranked clinical neurology journals and 23rd among 127 ranked oncology journals.

Not only did Dr. Bigner build Neuro-Oncology from the ground up, but he also secured the support of SNO, the Japan Society for Neuro-Oncology, the European Association for Neuro-Oncology, and the World Federation of Neuro-Oncology Societies to help create a truly global publication. His early vision for this journal was (and still is) shared by the Pediatric Brain Tumor Foundation of the United States, whose initial grant allowed the establishment of the journal and whose continued support still plays a vital role in its operations.

Upon their assuming the helm at N-O, Drs. Yung and James implemented new activities to further improve the journal. One of their first actions was to institute an online survey of N-O’s readers, querying them regarding what they want from the journal. This survey garnered substantial feedback, and the readers’ input is helping to shape plans for future publication.

The survey found that fully half of N-O’s readers are neuro-oncologists proper, with another 19% neurosurgeons. Other fields are well-represented, too, chief among them basic science (14%), pediatrics (10%), radiation oncology (8%), pathology (8%), and neurology (7%). Also responding were biostatisticians, nurses, and psychologists. Ninety percent of the respondents reported always or frequently reading Neuro-Oncology (the next top two vote recipients in this category were the Journal of Clinical Oncology and Cancer Research—both of which are renowned in the larger oncology community). Clearly, those who receive N-O rate its overall quality very high.

The survey results also showed that 84% of the respondents wanted to see special-topics issues or supplements, and as a result the journal has already put together a special section on pediatric neuro-oncology (see sidebar). In addition, prominent authorities are being invited to write review articles that give readers their unique perspectives on the most important issues in neuro-oncology today. Even the look of N-O has been updated. A new, clean, vibrant cover uses bolder graphics, more color, and text that highlights specific content on the pages inside.

The biggest change planned for the journal, however, is an increase in frequency. As the number of clinicians and investigators involved with the study and treatment of brain tumors continues to grow, the more there is to share with the scientific community—which has proved to be something of a challenge for the journal. The journal’s steady rise in impact factor and its recent move to online manuscript submission have contributed to a dramatic increase in submissions. In 2006, 258 new manuscripts were registered in the online Editorial Manager system; for 2007, it is on pace to receive almost 400 manuscripts for the year. Not to mention the review articles, book reviews, or other special topics papers that are commissioned. “Even were we to tighten our already-rigorous standards,” the editors wrote in their April 2007 editorial, “many excellent manuscripts would have to be excluded in order to stay within our yearly page number limit. This, in turn, would be a disservice to the journal’s authors and readers.”

To alleviate the backlog and give deserving authors their due, the last two 2007 issues were expanded to include more original articles, as well as the SNO Annual Meeting abstracts in October. And a more longstanding solution is in the works: beginning in February 2008, Neuro-Oncology will be published six times a year. This expansion will increase the journal’s ability to publish more original research articles in a more timely manner, will invigorate the news section, and will increase the frequency with which it can present special focus sections, supplements, reviews, and other in-depth analyses of the most important developments and challenges facing neuro-oncologists and others fighting CNS cancers.

Finally, to ensure that all of the journal’s sponsoring organizations receive appropriate representation in editorial decision making, SNO and the new editors have consulted with EANO and JSNO to formalize the organizations’ relationships with the journal. The result is a slight but meaningful change in the structure of the editorial leadership team; for more details, see the inset on this page.

Going forward, the Neuro-Oncology management team will remain mindful of the support it receives from the journal’s many contributors—the authors, readers, reviewers, and overseas editors who are responsible for ensuring that Neuro-Oncology is the must-read journal in its field.

At the November 2006 Annual Meeting of the Society for Neuro-Oncology (SNO), the Board of Directors considered and approved a new editorial structure for Neuro-Oncology, SNO’s official journal. This new structure, detailed below, served to regularize and formalize the relationship between the journal and the three societies that have adopted it as their official publication: SNO, the European Association for Neuro-Oncology (EANO), and the Japan Society for Neuro-Oncology (JSNO). Within this new structure, each organization will serve the journal with a representative at the editorial level. The new editorial structure is as follows:

W. K. Alfred Yung, Editor in Chief
C. David James, Executive Editor, SNO
Michael Weller, Executive Editor, EANO
Ryo Nishikawa, Executive Editor, JSNO

N-O’s first special focus issue reflects wide spectrum of research

Neuro-Oncology’s first special focus issue (April 2007) highlighted a topic that reflects the journal’s deepest roots: pediatric neuro-oncology. For this issue, the editors selected five papers covering a broad array of tumor types, from astrocytic tumors to gliomas and medulloblastomas, and addressing a range of investigative questions, from molecular pathogenesis to the clinical use of advanced cytotoxic agents. This pediatric focus issue also included abstracts from the 12th International Symposium on Pediatric Neuro-Oncology (ISPNO), held June 6-9, 2006, in Nara, Japan.

This initial effort to aggregate current thinking on a specific topic provides a glimpse of what the editors hope Neuro-Oncology will achieve in the long term: in-depth analyses of some of the most important questions confronting the neuro-oncology community. This is no simple task, given the journal’s diverse, multidisciplinary readership. However, by identifying and publishing papers that look at specific subspecialties in neuro-oncology, they hope to build a databank of state-of-the-art knowledge.
The SNO Nursing Initiative

The group's proposal to create a formalized nursing section through the creation of a Nursing Committee within SNO received overwhelming support from the Board. It was agreed that the responsibilities of the new SNO Nursing Committee would include:

- Advising the SNO Board regarding education and other matters significant to neuro-oncology nursing.
- Coordinating educational activities in conjunction with the Education and Scientific Program Committee, Awards Committee, Education Committee and Publications Committee.
- Introducing meeting topics relating to quality of life and symptom management.

The goal expressed by the group is to see nursing and other non-physician professionals participating more in scientific session presentations that address quality of life and symptom management issues. Efforts will be made to enhance the collegial relationship of nursing with other disciplines, rather than establishing nursing as a separate entity within SNO. Several recommendations to achieve this have been put forth:

- Consider a presentation on a specific symptom, for example, fatigue, and design a multidisciplinary panel to address it from a variety of facets.
- Offer opportunities for Round Table discussions on QOL/Symptom management topics.

In moving forward the Nursing Committee has identified representatives to the Scientific Program Committee, Awards Committee, Education Committee and Publications Committee.

The SNO Nursing Committee affords the opportunity for many exciting collaborative endeavors. Following a presentation by Mr. & Mrs. Sontag in November, a research project was identified by some of the nurses in attendance. Many opportunities also exist for initiatives addressing quality of life issues, symptom management, patient education, and evidenced-based practice. There was great enthusiasm and many ideas generated by the nurses at the initial meeting. It is expected that this Committee will serve as a forum for nurses within SNO to identify and address issues common in the care of patients with CNS neoplasms.

Noreen M. Leahy, MS, RN, CS

Expanding Opportunities for All Members

In keeping with our mission to foster multidisciplinary exchange and to make our Society as inclusive as possible, SNO reached out this year to nurses working in the field of neuro-oncology. A core group led by Noreen Leahy, has set the ground work for making a more visible role for nurses within SNO.

SNO International Outreach

In 2006-7 the leadership of SNO was pleased to announce the creation of the SNO International Outreach Committee. This new committee is an effort by SNO to facilitate neuro-oncology activities on an international level with an added emphasis on outreach efforts in third world countries.

Specific initiatives being developed by the committee include the international dissemination of neuro-oncology educational materials via the SNO website or with links to other web sites, including taped lectures, teaching files, syllabus lectures of SNO meetings or international libraries, and extending the availability of the SNO journal Neuro-Oncology. Ultimately, it is hoped that these initiatives will lead to CME activities organized through SNO.

At the present time, the Committee is identifying and communicating with pertinent individuals in the targeted countries and regions, as well as individuals in North America and Western Europe with significant connections with third world neuro-oncology communities, who it is hoped will be able to facilitate the above-mentioned interactions.

Jonathan Finlay, MB ChB

A Global Focus

SNO is grateful to Schering-Plough for a very generous grant to video tape the sessions from the recent 2006 Annual Meeting in Orlando. Comprised of twelve disks in all, this DVD program will be distributed to neuro-oncology professionals in emerging areas who might not otherwise have the ability to benefit from the SNO meeting.

It is important to remember that a far higher proportion of the population in the majority of “third world” countries are within the pediatric and adolescent age group. While the 5 year relative survival from brain cancer in the USA in patients under 19 years of age has improved by 25% over a 15 year period to 73% (in the period 1995-2000), similar survival for young patients in “third world” countries are likely no better than one-tenth of that! Thus, the Committee is determined to assure partnerships with both pediatric and adult neuro-oncologists in “third world” countries. Those of us who have been sufficiently privileged to train, live and work in the “developed” world have, I firmly believe, a moral and ethical responsibility to work towards enhancing the lot of those patients living in the “third world” whose brain tumors we strive to understand and thereby cure, through the kind of outreach program envisioned by the SNO leadership in establishing this Committee.
### ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$179,932</td>
</tr>
<tr>
<td>Investments</td>
<td>857,373</td>
</tr>
<tr>
<td>Contributions receivable - Short-term</td>
<td>43,000</td>
</tr>
<tr>
<td>Contributions receivable - Long-term</td>
<td>36,000</td>
</tr>
<tr>
<td>Endowment Assets</td>
<td>176,505</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$1,292,810</strong></td>
</tr>
</tbody>
</table>

### LIABILITIES AND NET ASSETS

#### LIABILITIES

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Payroll liabilities</td>
<td>$2,919</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>77,200</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>80,119</strong></td>
</tr>
</tbody>
</table>

#### NET ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td></td>
</tr>
<tr>
<td>Designated</td>
<td>98,505</td>
</tr>
<tr>
<td>Undesignated</td>
<td>1,036,186</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>1,212,691</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Temporarily restricted</td>
<td></td>
</tr>
<tr>
<td>Permanently restricted</td>
<td></td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$1,292,810</strong></td>
</tr>
</tbody>
</table>

### REVENUES AND OTHER SUPPORT

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and grants</td>
<td>$678,263</td>
<td></td>
<td></td>
<td>$678,263</td>
</tr>
<tr>
<td>Membership dues</td>
<td>45,895</td>
<td></td>
<td></td>
<td>45,895</td>
</tr>
<tr>
<td>Meetings</td>
<td>234,780</td>
<td></td>
<td></td>
<td>234,780</td>
</tr>
<tr>
<td>Investment earnings</td>
<td>77,162</td>
<td></td>
<td></td>
<td>77,162</td>
</tr>
<tr>
<td>Endowment earnings</td>
<td>32,307</td>
<td></td>
<td></td>
<td>32,307</td>
</tr>
<tr>
<td><strong>Total Revenues &amp; Support</strong></td>
<td><strong>1,068,407</strong></td>
<td></td>
<td></td>
<td><strong>1,068,407</strong></td>
</tr>
</tbody>
</table>

### EXPENSES

#### Program Services:

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Journal</td>
<td>40,026</td>
<td></td>
<td></td>
<td>40,026</td>
</tr>
<tr>
<td>Victor Levin Founders Society</td>
<td>42,803</td>
<td></td>
<td></td>
<td>42,803</td>
</tr>
<tr>
<td>Meetings</td>
<td>311,512</td>
<td></td>
<td></td>
<td>311,512</td>
</tr>
<tr>
<td>Membership</td>
<td>28,848</td>
<td></td>
<td></td>
<td>28,848</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>491,676</strong></td>
<td></td>
<td></td>
<td><strong>491,676</strong></td>
</tr>
</tbody>
</table>

#### Supporting Services:

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>40,787</td>
<td></td>
<td></td>
<td>40,787</td>
</tr>
<tr>
<td>Fund raising</td>
<td>27,700</td>
<td></td>
<td></td>
<td>27,700</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>428,487</strong></td>
<td></td>
<td></td>
<td><strong>428,487</strong></td>
</tr>
</tbody>
</table>

### CHANGE IN NET ASSETS - FYE June 30, 2007

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>576,731</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### NET ASSETS - June 30, 2006

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>557,960</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### NET ASSETS - June 30, 2007

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$1,134,691</strong></td>
<td>$78,000</td>
<td></td>
<td></td>
<td><strong>1,212,691</strong></td>
</tr>
</tbody>
</table>

Officers, Board of Directors and Committees

Society for Neuro-Oncology

Officers and Board of Directors

President
Abhijit Guha, MD

Vice President
Mark R. Gilbert, MD

Secretary-Treasurer
Corey Raffel, MD, PhD

Board of Directors

Timothy Cloughesy, MD
Jonathan Finlay, MD
Frederick F. Lang MD
Glenn Leser, MD
David N. Louis, MD
Minesh P. Mehta, MD
Christina A. Meyers, PhD
Erwin Van Meir, PhD

Past Presidents

Victor A. Levin, MD
Mitchel S. Berger, MD
Stuart A. Grossman, MD
Edward G. Shaw, MD
Michael D. Prados, MD

Foundation Board

Edward G. Shaw, MD
Victor A. Levin, MD
Mitchel S. Berger, MD

Journal Editor in Chief
WK Alfred Yung, MD

Executive Editor, SNO
C. David James, PhD

Awards Committee
The Awards Committee is charged with developing criteria for SNO awards, annually reviewing award candidates, and forwarding to the Board a list of Awards and award recipients to be honored at the Annual Meeting.
Chair: Michael E. Berens, PhD
Vice Chair: Kenneth Aldape, MD

Audit Committee
The Audit Committee is a newly formed committee and is composed of a Chair and Vice Chair, the Vice President, the Secretary-Treasurer, the Executive Director, and additional designated members as necessary. The committee has the responsibility of overseeing annual internal audits of Society financial affairs, and conveying an annual report to the President and the Board, who may approve review of the audit by external committees as needed. The committee also advises and makes recommendations to the Board of Directors based on findings of such audits.
Chair: Gene Barnett, MD
Vice Chair: Stephen Sagar, MD

Bylaws Committee
The Bylaws Committee reviews the Bylaws at least annually (more frequently as issues arise) and makes recommendations for revision as necessary. Members of this committee shall also review any proposed changes and advise the Board of Directors on proposed revisions.
Chair: Kurt A. Jaekle, MD
Vice Chair: Ian McCutcheon, MD

Education Committee
The Education Committee advises the Board of Directors on all projects concerning education in the field of neuro-oncology, including planning of the Education Day.
Chair: Frederick F. Lang, MD
Vice Chair: Lois Lampson, PhD

Administrative Staff

Executive Director
J. Charles (Chas) Haynes, J.D.

Chief Administrative Officer
Jan Esenwein

Administration
Linda Greer

Society for Neuro-Oncology
4617 Birch Street
Bellaire, TX 77401

tel 713.349.0952
fax 832.201.8129

www.soc-neuro-onc.org
Future Sites Committee
The Future Sites Committee reviews potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue.
Chair: Walter A. Hall, MD
Vice Chair: Lynn Ashby, MD

International Outreach Committee
The International Outreach Committee is another newly formed committee. It is composed of a Chair and Vice-Chair, the President and Vice President of the Society, and other representative International members recommended by the Chair or President, as approved by the Board of Directors. The committee will have the responsibility of advising and making recommendations to the Board of Directors on international affairs, promoting international membership, and issues of importance to the international conduct of the Society.
Chair: John G. Golfinos, MD
Vice Chair: Russell Pieper, PhD

Membership Committee
The Membership Committee is charged with reviewing and voting on all applicants for membership. Responsibilities include the evaluation of a member’s professional conduct as requested by a majority of the Board of Directors, and development of initiatives to promote membership.
Chair: Larry Kun, MD
Vice Chair: Arnab Chakravarti, MD

Nursing Committee
The Neuro-oncology Nursing Committee is a third new committee. It is composed of a Chair and Vice Chair, and other members who will have the responsibility of advising and making recommendations to the Board of Directors on all projects concerning education and other significant matters related to the field of neuro-oncology nursing. This committee also coordinates educational activities for the nursing membership, including workshops, satellite symposia or special sessions involving neuro-oncology nursing. The committee will coordinate the program for these educational activities in conjunction with the Education and Scientific Program Committees, and such programs will primarily be conducted at the Annual Society or World Federation Meetings.
Chair: Nooren Lahey, MS
Vice Chair: Vanessa Nestor, MS

Publications Committee
The Publications Committee is a fourth new committee and is composed of a Chair and Vice Chair, the Executive Director and Chief Administrative Officer, the Secretary-Treasurer, and Chairs of the Awards and Education Committees. This committee has the responsibility of advising and making recommendations to the Board of Directors on issues pertaining to publications of the Society, including but not limited to the officially-endorsed Journal of the Society.
Chair: Oliver Bogler, PhD
Vice Chair: Daphne Haas-Kogan, MD

Scientific Program Committee
The Scientific Program Committee supervises and coordinates all aspects of upcoming SNO Scientific Meetings, including selection of platform presentations, keynote speakers, expert sessions, and other invited speakers. Members will review meeting evaluations, solicit other comments on meeting structure and organization, and recommend changes as appropriate.
Chair: WK Alfred Yung, MD
Vice Chair: Russell Pieper, PhD

SNO Partners
(current as of fiscal year ending June 30th, 2007)

Platinum Level
American Brain Tumor Association
Genentech
Merck KGaA
Neopharm
Pediatric Brain Tumor Foundation
Schering-Plough Oncology
Sontag Foundation

Gold Level
Brain Tumor Society
MGI PHARMA
Eli Lilly

Silver Level
Pfizer

Bronze Level
Amen
Cellidex Therapeutics
Cytoc
National Brain Tumor Foundation Neurobiological Technologies
Northwest Biotherapeutics
TransMolecular

President’s Club
Dean
Jeffrey S. Brindile, MD
Stanimir R. Burgunska, MD, PhD
Morris D. Groves, MD, JD
Abhijit Guha, MD
Kevin Murray, MD
Raymond E. Sawaya, MD
Edward G. Shaw, MD
Childhood Brain Tumor Foundation

Professor
Peter McL. Black, MD
Jonathan L. Finlay, MD
Gregory N. Fuller, MD, PhD
John G. Golfinos, MD
Walter A. Hall, MD

Victor Levin Founders Society
Victor A. Levin, MD
Brian L. Greenspun
Harold and Pamela Ruttenberg
Schering-Plough Corporation
WK Alfred Yung, MD

Associate
Oliver Bogler, PhD
Michael R. Chicoine, MD
Ali K. Choucair, MD
Charles Hesdorffer, MD
Carol Kruchko
Christina A. Meyers, PhD
Elisabeth W. Newcomb, MD
Michael A. Vogelbaum, MD, PhD

Fellow
Jeffrey Allen, MD
Henry Brem, MD
Michael Custonimo, MD
Walidemar Debinski, PhD
Bonnie Feldman
Karen L. Fink, MD, PhD
Alexandra Flowers, MD
Peter A. Forsyth, MD, FRCPC
Henry S. Friedman, MD
Jeffrey Goldman, MD
Robert Jenkins, MD, PhD
Arie Perry, MD
Suraskk Phuphanitch, MD
Jeffrey Raines, MD
Gerald Rosen, MD
Adrienne C. Scheck, PhD
Jeffrey W. Sherman, MD
Robert L. Tufel
Mission
SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

Vision
SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.

SNO Members
- Neurosurgery 23%
- Neuro-oncology 22%
- Radiation Oncology 15%
- Basic Science 10%
- Medical Oncology 10%
- Pediatrics 7%
- Associate 6%
- Pathology 5%
- Other 2%
- Medical Oncology 10%
- Pediatrics 7%
- Associate 6%
- Pathology 5%
- Other 2%
- Basic Science 10%
- Radiation Oncology 15%
- Neuro-oncology 22%
- Neurosurgery 23%